ClinicalTrials.gg
RecruitingNCT07530497REBARUpdated Nov 19, 2026

Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures

An observational study in Fracture; Pelvic, Insufficiency Fractures and Fragility Fracture, sponsored by SI-BONE, Inc.. Recruiting at 4 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by SI-BONE, Inc. · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 19, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Planned enrollment
14th of 26
120 · median 160
Started
2026
with 5 others
Observational
26 of 133
8 open now
Primary completion
2028-02
later than 22 of 30 live
Registered
131st of 133
by date

Among the 133 studies in Hip Fractures with a site in United States, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2026, is one of 26 observational ones, reaches primary completion later than 22 of the 30 other live ones, and was the 131st registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate outcomes in patients treated with iFuse TORQ TNT for pelvic fragility fractures.

Read the detailed description

REBAR is a prospective, multicenter, single arm, post-market observational study conducted in a real-world setting on the usage of iFuse TORQ TNT.

03

Conditions studied

  • Fracture; Pelvic
  • Insufficiency Fractures
  • Fragility Fracture
  • Sacroiliac; Fusion
  • Sacroiliac Joint Disruption
  • Sacroiliac Joint Dysfunction

Keywords

  • Fragility Fracture
  • pelvic fracture
  • Osteoporotic pelvic fracture
  • Fragility Fracture of the pelvis
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target patient population is patients with fragility fractures of the pelvis (FFP) in whom surgical fracture fixation is performed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 60 years of age at screening
  2. Pelvic pain correlating with fracture location that began EITHER within 6 weeks of a known low-energy traumatic event, OR pelvic insufficiency fracture with pain that is limiting mobility
  3. Diagnostic imaging (X-ray and CT) showing fracture of the pelvis that correlates with pain location
  4. Patient is scheduled for pelvic fixation using at least one iFuse TORQ TNT
  5. Patient and/or patient's legally authorized representative (LAR) understands and is willing and able to provide written
  6. Patient agrees to comply with study schedule of assessments
  7. Patient and/or patient's proxy can complete study-related surveys
  8. Patient was able to ambulate prior to index fracture

Exclusion criteria

Exclusion Criteria:

  1. Any known anatomic issues that could prevent placement of iFuse TORQ TNT
  2. Implants already in the pelvis (e.g. lumbopelvic fixation) that could interfere with placement of the study device(s)
  3. Patient requires lumbosacral pelvic fixation as part of index procedure
  4. Prominent neurologic or uncontrolled psychiatric condition that would interfere with study participation or regaining of physical function related to pelvic fracture and is unable to provide a health care proxy to complete study assessments.
  5. Estimated lifespan \< 12 months
  6. Presence of tumor, lytic lesion, infection, or soft tissues that precludes safe internal fixation
  7. Not candidate for surgery due to underlying medical illness
  8. Social situation that makes 12-month follow-up unlikely
  9. History of recent (within 1 year) non-index pelvic fracture with non-union
  10. Other clinically active fragility fracture of spine, hip or arms/legs that could impair recovery from sacral fracture
  11. Known allergy to titanium or titanium alloys
  12. Known or suspected active drug or alcohol abuse, including opioids
  13. Patient is a prisoner or ward of the state
  14. Patient is already participating in an clinical trial that may interfere with implant placement or study follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • FFP using iFuse TORQ TNT.

    Patients with fragility fractures of the pelvis (FFP) treated with surgical fixation using iFuse TORQ TNT.

    Device: iFuse TORQ TNT Implant System

Interventions

  • DeviceiFuse TORQ TNT Implant System

    FDA-clear implant used for fracture fixation of the pelvis, including acute, non-acute, and non-traumatic fractures and sacroiliac joint fusion for sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis.

06

What researchers measure

Primary outcomes

  1. Composite Measure

    The participant is considered a success if all of the following apply: * No breakage of study device on any radiographic study * No detectable migration or backout of study device compared to immediate postop or end-of-procedure view * No revision surgery related to the study device

    Time frame: 6-months

Secondary outcomes

  1. Safety endpoint: Proportion of Participants with ≥1 Serious Adverse Event (SAE)

    Proportion of participants with SAE probably or definitely related to study device or device placement procedure

    Time frame: 12 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There are currently no plans to share but IPD may be shared with qualified researchers upon reasonable request, subject to sponsor approval and data use agreements.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

Of 124 observational studies under Hip Fractures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Twin Cities Orthopedics · Edina, United States
  • Cedars-Sinai Medical Center · Los Angeles, United States
across 2 updates, Nov 2, 2026 – Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    1 site added
    Show site
    • Cedars-Sinai Medical Center · Los Angeles, United States
  2. Nov 2, 2026
    1 site added
    Show site
    • Twin Cities Orthopedics · Edina, United States
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07530497
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Aug 24, 2026
Primary completion
Feb 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Director of Clinical Affairs
Contact
clinicalaffairs@si-bone.com
408-207-0700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion